How CIMZIA Works For You

See CIMZIA In Action


While pain relievers may provide temporary relief for symptoms of non-radiographic axial spondyloarthritis (nr-axSpA), they do not address the underlying cause of the disease, which is inflammation. ClMZIA is the first and only therapy of its kind for nr-axSpA* proven to improve symptoms and disease activity over time. See how CIMZIA could work for you.

*CIMZIA is an anti-tumor necrosis factor (TNF) biologic.

CIMZIA® | Disease Activity. See full information on this page.
Improved Disease Activity

In a clinical trial, nearly 5 out of 10 people taking CIMZIA had major improvement in disease activity within 52 weeks—for some in as fast as 2 weeks.†

†47% of CIMZIA patients at 52 weeks vs. 7% of placebo patients; 21% of CIMZIA patients at 2 weeks vs. 1% of placebo patients.

CIMZIA® | Spinal Pain. See full information on this page.
Less Spinal Pain

People on CIMZIA experienced 33% less back pain than placebo-treated patients at week 12.

In a clinical trial, patients on CIMZIA experienced these results. Results shown above are based on a dose of 200 mg every two weeks. Results may vary; every person taking CIMZIA is different and responds differently to therapy.

Join our mailing list and get ongoing support for your nr-axSpA symptoms.

The Logic of a Biologic Like CIMZIA

CIMZIA is a biologic, meaning it is a drug derived from living sources that copy the effects of substances naturally made by your body’s immune system. As an anti-tumor necrosis factor (TNF) biologic, CIMZIA works to block the extra TNF that leads to inflammatory pain. Learn more about TNF and why an anti-TNF may be the most appropriate treatment for nr-axSpA symptoms.

The CIMZIA doctor discussion guide is available for download to assist with your next conversation with your rheumatologist

How Disruptive Is Your Inflammatory Back Pain?

Let's take a look at how you're managing your symptoms. If your back pain has lasted 3 months or longer and worsens with rest, you may have inflammation caused by non-radiographic axial spondyloarthritis.